Literature DB >> 8175966

Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide.

U Renner1, S Brockmeier, C J Strasburger, M Lange, J Schopohl, O A Müller, K von Werder, G K Stalla.   

Abstract

The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism. To determine the effect of GHRP on human somatotroph cells in vitro, we stimulated cell cultures derived from 12 different human somatotroph adenomas with GHRP alone and in combination with GH-releasing hormone (GHRH), TRH, and the somatostatin analog octreotide. GH secretion of all 12 adenoma cultures could be stimulated with GHRP, whereas GHRH was active only in 6 adenoma cultures. In GHRH-responsive cell cultures, simultaneous application of GHRH and GHRP had an additive effect on GH secretion. TRH stimulated GH release in 4 of 7 adenoma cultures; in TRH-responsive cell cultures there was also an additive effect of GHRP and TRH on GH secretion. In 5 of 9 adenoma cultures investigated, octreotide inhibited basal GH secretion. In these cell cultures, GHRP-induced GH release was suppressed by octreotide. In 5 of 5 cases, the protein kinase-C inhibitor phloretin partly inhibited GHRP-stimulated GH release, but not basal GH secretion. In summary, GH secretion was stimulated by GHRP in all somatotroph adenomas investigated, indicating that its unknown receptor and signaling pathway are expressed more consistently in somatotroph adenoma cells than those for GHRH, TRH, and somatostatin. Our data give further evidence that GHRP-stimulated GH secretion is mediated by a receptor different from that for GHRH or TRH, respectively, and that protein kinase-C is involved in the signal transduction pathway. Because human somatotroph adenoma cell cultures respond differently to various neuropeptides (GHRH, TRH, somatostatin, and others), they provide a model for further investigation of the mechanism of action of GHRP-induced GH secretion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175966     DOI: 10.1210/jcem.78.5.8175966

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Overexpression of stimulatory G protein alpha-subunit is a hallmark of most human somatotrophic pituitary tumours and is associated with resistance to GH-releasing hormone.

Authors:  C Hamacher; M Bröcker; E F Adams; T Lei; R Fahlbusch; M Buchfelder; M Derwahl
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

2.  Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.

Authors:  S Grottoli; E Arvat; C Gauna; B Maccagno; J Ramunni; R Giordano; M Maccario; R Deghenghi; E Ghigo
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

Review 3.  Hypothalamic and hypophyseal regulation of growth hormone secretion.

Authors:  M T Bluet-Pajot; J Epelbaum; D Gourdji; C Hammond; C Kordon
Journal:  Cell Mol Neurobiol       Date:  1998-02       Impact factor: 5.046

Review 4.  Ghrelin in neuroendocrine organs and tumours.

Authors:  Chrysanthia A Leontiou; Giulia Franchi; Márta Korbonits
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 5.  Biologic activities of growth hormone secretagogues in humans.

Authors:  E Ghigo; E Arvat; R Giordano; F Broglio; L Gianotti; M Maccario; G Bisi; A Graziani; M Papotti; G Muccioli; R Deghenghi; F Camanni
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

6.  Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.

Authors:  C Chen; P Farnworth; S Petersenn; I Musgrave; B J Canny; I J Clarke
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.